ClinicalTrials.Veeva

Find clinical trials for Eczema in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias
Psoriasis

Eczema trials near Kansas City, KS, USA:

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE)

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema)....

Active, not recruiting
Atopic Dermatitis Eczema
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Phase 3

Arcutis Biotherapeutics
Arcutis Biotherapeutics

Saint Joseph, Missouri, United States and 91 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Saint Joseph, Missouri, United States and 41 other locations

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis Eczema
Drug: ANB032
Drug: Placebo

Phase 2

AnaptysBio
AnaptysBio

Saint Joseph, Missouri, United States and 52 other locations

Global Assessment for Atopic Dermatitis (vIGA-AD).Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Overland Park, Kansas, United States and 196 other locations

, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Leawood, Kansas, United States of America and 234 other locations

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Enrolling
Atopic Dermatitis
Combination Product: Rocatinlimab Prefilled Syringe

Phase 3

Amgen
Amgen

Leawood, Kansas, United States of America and 13 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Phase 3

Pfizer
Pfizer

Overland Park, Kansas, United States and 560 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Shawnee Mission, Kansas, United States and 318 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Leawood, Kansas, United States of America and 333 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Overland Park, Kansas, United States and 192 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems